Howe & Rusling’s Guardant Health GH Stock Holding History

Howe & Rusling’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-75	Closed	-$4K	–	607
2022 Q3	$4K	Hold	75	–	–	﹤0.01%	714
2022 Q2	$3K	Buy	+75	New	+$3.72K	﹤0.01%	787

Other funds holding GH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Howe & Rusling's GH Position: Q4 2022 in Review

Howe & Rusling sold out of Guardant Health (GH) in Q4 2022, closing a stake of 75 shares — an estimated $4K sold.

Howe & Rusling first reported a position in GH in Q2 2022 and held it in 2 quarters. The position peaked at $4K in Q3 2022. 290 funds tracked by Wall St. Rank hold GH as of Q4 2022.

Howe & Rusling reported no remaining Guardant Health position as of Q4 2022 after selling out during the quarter.
Howe & Rusling sold 75 Guardant Health shares in Q4 2022, an estimated $4K.
Howe & Rusling first reported a position in Guardant Health in Q2 2022 and held it in 2 quarters.
Howe & Rusling's Guardant Health position peaked at $4K in Q3 2022.
290 funds tracked by Wall St. Rank held Guardant Health as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.